Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Pre-Clinical Evaluation and Commercial Development of Anti-Tyrosine Kinase-Like Orphan Receptor 1 Antibody-Drug Conjugates for the Treatment of Human Cancers, 17459 [C1-2015-06486]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 62 / Wednesday, April 1, 2015 / Notices
information sharing; (5) provides
information technology services to CDC
programs and external partners
including modernization of legacy
applications; (6) provides IT project
management for two surveillance
programs—the National Notifiable
Disease Surveillance System and the
National Syndromic Surveillance
Program—including the development of
the CDC Platform and Message
Validation Processing System (CDCP–
MVPS) the BioSense application, and
the NEDSS Base System (NBS); (7)
develops, maintains, and improves
epidemiologic tools for data collection,
data management, and data analysis,
including Epi Info; (8) provides training,
technical assistance, and support to
public health partners and entities using
Epi Info for outbreak investigations,
studies, and surveillance; (9) provides
SMEs, specifications, and services for
standards-based data interchanges,
electronic messaging, vocabulary
management, message validation,
security and credential management,
routing and directory management; (10)
provides consultation and technical
assistance to CDC programs and to
external partners on technical and
informatics aspects of systems and tools
required or endorsed by CDC; (11)
provides Public Health Information
Network (PHIN) certification; and (12)
provides support, technical assistance,
and strategic counsel to CDC programs
for the transition from ICD–9 to ICD–10
(and future iterations).
Partnerships and Evaluation Branch
(CPNED). (1) Supports CDC and STLT
Programs in the conduct of national
surveillance; (2) supports and manages
STLT and partner organizations
cooperative agreements with regard to
fiscal support and monitoring of
expenditures; (3) coordinates the
development of Funding Opportunity
Announcements, Interim Progress
Report Guidance, and Continuation
Applications; (4) monitors activities of
partner organizations and STLT
cooperative agreements to assure
program goals, objectives and key
performance indicators are achieved; (5)
assesses technical assistance needs of
grantees and develops strategies to
address those needs; (6) collaborates
with other DHIS branches and programs
in the development of evaluation
criteria and performance measures for
program planning and improvement; (7)
leads and coordinates or develops and
implements guidelines, uniform
reporting procedures, performance
measures, and evaluation criteria for
STLT and other external partner
cooperative agreements and grants; (8)
VerDate Sep<11>2014
23:37 Mar 31, 2015
Jkt 235001
works with other DHIS branches to
synthesize, translate, and disseminate
evaluation findings, success stories, and
lessons learned; (9) coordinates and
supports Division training activities
related to analytic data bases and data
collection and information systems; (10)
develops and manages collaborative
relationships with grantees and partners
to increase awareness, understanding,
and support for DHIS initiatives and
priorities; (11) supports and facilitates
partnership outreach and
communications to existing and new
partners; (12) provides guidance and
support on the establishment and
governance of Communities of Practice
associated with DHIS programs; and
(13) provides leadership for
coordinating technical assistance and
support to other CDC programs, STLT
grantees, and other external partners or
organizations.
James Seligman,
Acting Chief Operating Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2015–07348 Filed 3–31–15; 8:45 am]
BILLING CODE 4160–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive Evaluation Option License
Agreement: Pre-Clinical Evaluation
and Commercial Development of AntiTyrosine Kinase-Like Orphan Receptor
1 Antibody-Drug Conjugates for the
Treatment of Human Cancers
Correction
In notice document 2015–06486
appearing on pages 15226–15227 in the
issue of Monday, March 23, 2015 make
the following correction:
On page 15226, in the third column,
under the DATES heading, in the last
line, ‘‘April 6, 2015’’ should read ‘‘April
7, 2015’’.
[FR Doc. C1–2015–06486 Filed 3–31–15; 8:45 am]
BILLING CODE 1505–01–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID FEMA–2015–0001; Internal
Agency Docket No. FEMA–B–1474]
Changes in Flood Hazard
Determinations
Federal Emergency
Management Agency, DHS.
AGENCY:
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
ACTION:
17459
Notice.
This notice lists communities
where the addition or modification of
Base Flood Elevations (BFEs), base flood
depths, Special Flood Hazard Area
(SFHA) boundaries or zone
designations, or the regulatory floodway
(hereinafter referred to as flood hazard
determinations), as shown on the Flood
Insurance Rate Maps (FIRMs), and
where applicable, in the supporting
Flood Insurance Study (FIS) reports,
prepared by the Federal Emergency
Management Agency (FEMA) for each
community, is appropriate because of
new scientific or technical data. The
FIRM, and where applicable, portions of
the FIS report, have been revised to
reflect these flood hazard
determinations through issuance of a
Letter of Map Revision (LOMR), in
accordance with Title 44, Part 65 of the
Code of Federal Regulations (44 CFR
part 65). The LOMR will be used by
insurance agents and others to calculate
appropriate flood insurance premium
rates for new buildings and the contents
of those buildings. For rating purposes,
the currently effective community
number is shown in the table below and
must be used for all new policies and
renewals.
DATES: These flood hazard
determinations will become effective on
the dates listed in the table below and
revise the FIRM panels and FIS report
in effect prior to this determination for
the listed communities.
From the date of the second
publication of notification of these
changes in a newspaper of local
circulation, any person has 90 days in
which to request through the
community that the Deputy Associate
Administrator for Mitigation reconsider
the changes. The flood hazard
determination information may be
changed during the 90-day period.
ADDRESSES: The affected communities
are listed in the table below. Revised
flood hazard information for each
community is available for inspection at
both the online location and the
respective community map repository
address listed in the table below.
Additionally, the current effective FIRM
and FIS report for each community are
accessible online through the FEMA
Map Service Center at
www.msc.fema.gov for comparison.
Submit comments and/or appeals to
the Chief Executive Officer of the
community as listed in the table below.
FOR FURTHER INFORMATION CONTACT: Luis
Rodriguez, Chief, Engineering
Management Branch, Federal Insurance
and Mitigation Administration, FEMA,
SUMMARY:
E:\FR\FM\01APN1.SGM
01APN1
]]>Agencies
[Federal Register Volume 80, Number 62 (Wednesday, April 1, 2015)]
[Notices]
[Page 17459]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: C1-2015-06486]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up Exclusive Evaluation Option License
Agreement: Pre-Clinical Evaluation and Commercial Development of Anti-
Tyrosine Kinase-Like Orphan Receptor 1 Antibody-Drug Conjugates for the
Treatment of Human Cancers
Correction
In notice document 2015-06486 appearing on pages 15226-15227 in the
issue of Monday, March 23, 2015 make the following correction:
On page 15226, in the third column, under the DATES heading, in the
last line, ``April 6, 2015'' should read ``April 7, 2015''.
[FR Doc. C1-2015-06486 Filed 3-31-15; 8:45 am]
BILLING CODE 1505-01-P
